[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital de Clínicas Dr. Manuel Quintela\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100639304","invasive-evaluation-and-phenotype-guided-treatment-of-anoca-in-women-100639304",false,"NCT07593157","Invasive Evaluation and Phenotype-Guided Treatment of ANOCA in Women","Invasive Functional and Morphological Coronary Assessment Followed by Phenotype-Guided Multidisciplinary Treatment in Women With Angina and Non-Obstructive Coronary Arteries: A Prospective Single-Center Interventional Study","ANOCA-UY","Inclusion Criteria:\n\n* Female participants aged 35 to 75 years.\n* Symptoms compatible with stable angina or suspected myocardial ischemia.\n* Non-obstructive coronary arteries, defined as absence of angiographic stenosis greater than or equal to 50%.\n* Ability to undergo invasive coronary assessment and clinical follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Significant structural heart disease.\n* Severe left ventricular systolic dysfunction, defined as left ventricular ejection fraction \\\u003C40%.\n* Clinically relevant contraindication to adenosine or acetylcholine, including severe asthma, untreated high-grade atrioventricular block, or known hypersensitivity.\n* Active oncological disease or life expectancy less than 12 months.\n* Inability to complete the diagnostic or therapeutic study protocol.\n* Participation in another clinical study that could interfere with the present protocol.","FEMALE","35 Years","75 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This prospective single-center interventional study will include women with angina and non-obstructive coronary arteries. Participants will undergo a standardized invasive coronary assessment combining coronary physiology, acetylcholine provocation testing, and optical coherence tomography. The diagnostic protocol will identify functional and morphological mechanisms of angina, including microvascular dysfunction, epicardial vasospasm, microvascular spasm, endothelial dysfunction, functional epicardial disease, combined mechanisms, or normal coronary physiology.\n\nBased on the identified phenotype, participants will receive individualized multidisciplinary treatment, including targeted pharmacological therapy, adapted cardiovascular rehabilitation, and psycho-emotional support when indicated. Clinical follow-up will be performed at 1, 6, and 12 months to assess angina symptoms, quality of life, functional capacity, adherence to treatment, and cardiovascular events.",[28,29,30],"ANOCA - Angina With Non-obstructive Coronary Arteries","Coronary Microvascular Dysfunction (CMD)","Vasospastic Angina",[32,33,34,35,36],"Angina with non-obstructive coronary arteries","ANOCA","INOCA","Vasospastic angina","Coronary Microvascular Dysfunction","NOT_YET_RECRUITING","2026-05-15",{"date":40,"type":41},"2026-05-18","ACTUAL",{"date":38,"type":22},{"date":44,"type":22},"2029-04-30",{"name":46,"class":47},"Hospital de Clínicas Dr. Manuel Quintela","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100602724","early-phase-1-prucaloprida-vs-bisacodyl-as-a-stimulant-in-bowel-preparation-for-video-colonoscopy-in-adults-100602724","NCT07127237","Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults","Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults: A Randomized Clinical Trial","Inclusion Criteria:\n\n* All patients over 18 years of age.\n* Without prior colonic surgical interventions.\n* Who attend the Digestive Endoscopy service to undergo a colonoscopy.\n\nExclusion Criteria:\n\n* Patients who voluntarily choose not to participate in the study.\n* Pregnant women.\n* Patients with rectocolonic resections and\u002For ileostomies.\n* Inflammatory bowel disease.\n* Inadequate bowel preparation in a previous colonoscopy.\n* Suspected intestinal obstruction or perforation.\n* Intestinal intussusception.\n* Melena.\n* Oral iron intake within the last 10 days.\n* Emergency colonoscopies.\n* Hypersensitivity to any component of the bowel preparation solutions.\n* Chronic kidney disease on dialysis.\n* Uncorrected severe electrolyte imbalances.\n* Major psychiatric disorders.\n* Low intellectual quotient.\n* Severe constipation (≤ 1 bowel movement per week).\n* Chronic diarrhea with high frequency (≥ 4 daily bowel movements of uniformly decreased consistency for more than 4 weeks).\n* Decompensated cardiac diseases (ischemic heart disease, congestive heart failure, unstable angina, arrhythmias, and uncontrolled hypertension).\n* Ascites.",true,"ALL","18 Years",{"count":60,"type":22},124,[62],"EARLY_PHASE1","The objective of this randomized clinical trial is to compare prucalopride versus bisacodyl as a stimulant agent for bowel cleansing preparation prior to colonoscopy in patients undergoing the procedure at the Endoscopy Unit of the Hospital de Clínicas. The main research questions this study aims to answer are:\n\nIs prucalopride superior or equivalent to bisacodyl as a stimulant agent for bowel cleansing preparation before colonoscopy? Is the tolerability of prucalopride better, equivalent, or worse compared to bisacodyl? The investigators will compare the standard bowel cleansing preparation using polyethylene glycol (PEG) in combination with either bisacodyl or prucalopride as the stimulant agent.\n\nParticipants will be randomized into two groups, both receiving the same base preparation with different stimulant agents.",[65],"Bowel Preparation","2025-08-11",{"date":68,"type":41},"2025-08-17",{"date":70,"type":22},"2025-09",{"date":72,"type":22},"2026-02",{"name":46,"class":47},""]